Trials / Completed
CompletedNCT01412047
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
How does long term treatment with Soliris affect HAHA in PNH patients?
Detailed description
To determine the long term effect of Soliris (eculizumab) treatment on the presence of human anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.
Conditions
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-30
- First posted
- 2011-08-08
- Last updated
- 2017-10-18
Locations
14 sites across 10 countries: United States, Australia, Belgium, France, Germany, Ireland, Italy, Netherlands, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01412047. Inclusion in this directory is not an endorsement.